Davidson Investment Advisors raised its holdings in shares of Amgen, Inc. (NASDAQ:AMGN) by 45.4% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 57,573 shares of the medical research company’s stock after acquiring an additional 17,988 shares during the period. Davidson Investment Advisors’ holdings in Amgen were worth $10,734,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of AMGN. Janus Henderson Group PLC grew its position in Amgen by 3,664.7% during the second quarter. Janus Henderson Group PLC now owns 3,699,351 shares of the medical research company’s stock valued at $637,139,000 after acquiring an additional 3,601,087 shares during the last quarter. FMR LLC grew its position in Amgen by 4.8% during the second quarter. FMR LLC now owns 56,999,572 shares of the medical research company’s stock valued at $9,817,037,000 after acquiring an additional 2,587,041 shares during the last quarter. Renaissance Technologies LLC grew its position in Amgen by 40.9% during the second quarter. Renaissance Technologies LLC now owns 3,400,145 shares of the medical research company’s stock valued at $585,607,000 after acquiring an additional 986,700 shares during the last quarter. BlackRock Inc. grew its position in Amgen by 1.9% during the second quarter. BlackRock Inc. now owns 49,451,203 shares of the medical research company’s stock valued at $8,516,980,000 after acquiring an additional 909,689 shares during the last quarter. Finally, Nordea Investment Management AB grew its position in Amgen by 12.9% during the second quarter. Nordea Investment Management AB now owns 7,040,599 shares of the medical research company’s stock valued at $1,212,602,000 after acquiring an additional 806,119 shares during the last quarter. Institutional investors and hedge funds own 78.48% of the company’s stock.

In related news, EVP Sean E. Harper sold 1,525 shares of Amgen stock in a transaction dated Monday, November 13th. The stock was sold at an average price of $171.58, for a total value of $261,659.50. Following the completion of the sale, the executive vice president now directly owns 57,631 shares in the company, valued at approximately $9,888,326.98. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Carbonnel Francois De sold 4,000 shares of Amgen stock in a transaction dated Wednesday, November 8th. The stock was sold at an average price of $173.61, for a total value of $694,440.00. The disclosure for this sale can be found here. Insiders have sold 8,575 shares of company stock valued at $1,508,836 in the last three months. Insiders own 0.19% of the company’s stock.

A number of research analysts have commented on the stock. BidaskClub upgraded shares of Amgen from a “sell” rating to a “hold” rating in a research report on Thursday, January 18th. JPMorgan Chase & Co. increased their price target on shares of Amgen from $184.00 to $189.00 and gave the company a “neutral” rating in a research report on Wednesday. Royal Bank of Canada restated a “hold” rating and issued a $189.00 target price on shares of Amgen in a report on Wednesday. Argus upgraded shares of Amgen from a “hold” rating to a “buy” rating and raised their target price for the stock from $192.33 to $220.00 in a report on Tuesday. Finally, Oppenheimer set a $205.00 target price on shares of Amgen and gave the stock a “buy” rating in a report on Friday, January 5th. Fifteen analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. Amgen has an average rating of “Hold” and an average price target of $191.28.

Shares of Amgen, Inc. (NASDAQ AMGN) opened at $190.08 on Friday. The company has a quick ratio of 5.72, a current ratio of 6.07 and a debt-to-equity ratio of 1.05. The company has a market capitalization of $137,980.00, a price-to-earnings ratio of 17.17, a P/E/G ratio of 2.82 and a beta of 1.36. Amgen, Inc. has a 52 week low of $152.16 and a 52 week high of $196.03.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Wednesday, October 25th. The medical research company reported $3.27 EPS for the quarter, beating the consensus estimate of $3.11 by $0.16. The business had revenue of $5.77 billion during the quarter, compared to analyst estimates of $5.75 billion. Amgen had a return on equity of 29.90% and a net margin of 35.54%. The company’s revenue for the quarter was down .7% on a year-over-year basis. During the same quarter last year, the firm posted $3.02 earnings per share. analysts expect that Amgen, Inc. will post 12.69 EPS for the current fiscal year.

Amgen announced that its board has approved a stock repurchase program on Wednesday, October 25th that allows the company to repurchase $5.00 billion in shares. This repurchase authorization allows the medical research company to purchase shares of its stock through open market purchases. Stock repurchase programs are often a sign that the company’s board believes its shares are undervalued.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 8th. Shareholders of record on Thursday, February 15th will be given a dividend of $1.32 per share. The ex-dividend date is Wednesday, February 14th. This represents a $5.28 annualized dividend and a yield of 2.78%. This is a positive change from Amgen’s previous quarterly dividend of $1.15. Amgen’s dividend payout ratio (DPR) is currently 41.55%.

TRADEMARK VIOLATION NOTICE: “Davidson Investment Advisors Acquires 17,988 Shares of Amgen, Inc. (AMGN)” was first reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international trademark & copyright laws. The correct version of this report can be read at https://theolympiareport.com/2018/01/26/davidson-investment-advisors-acquires-17988-shares-of-amgen-inc-amgn.html.

Amgen Company Profile

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.